Breaking News Instant updates and real-time market news.

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13

G1 presents additional data from randomized Phase 2 trial in first-line SCLC

G1 Therapeutics announced data from new analyses of its randomized Phase 2 clinical trial of trilaciclib in combination with etoposide/carboplatin for the treatment of first-line small cell lung cancer. The analyses demonstrated clinically meaningful improvements for neutrophil, red blood cell and lymphocyte measures in patients treated with trilaciclib compared to placebo. With regard to lymphocytes, trilaciclib preserved or improved B cell and T cell subset counts, including activated CD8+ cells, and increased CD8+/regulatory T cell and activated CD8+/regulatory T cell ratios in peripheral blood compared to placebo. The company reported topline data from this trial in March 2018 showing robust myelopreservation benefits of trilaciclib. Consistent with previously reported results, new analyses demonstrated that trilaciclib reduced clinically relevant consequences of chemotherapy-induced myelosuppression versus placebo. Overall, there were fewer greater than or equal to Grade 3 treatment emergent adverse events with trilaciclib compared to placebo, mostly due to lower number of greater than or equal to Grade 3 hematologic TEAEs.

  • 27

    Nov

GTHX G1 Therapeutics
$46.88

-0.07 (-0.15%)

09/18/18
NEED
09/18/18
NO CHANGE
Target $76
NEED
Buy
G1 Therapeutics price target raised to $76 from $60 at Needham
Needham analyst Chad Messer raised his price target on G1 Therapeutics to $76 and kept his Buy rating, citing the company's announcement yesterday of amended phase 2 trial protocol for trilaciclib testing in combination with chemotherapy and Tecentrq. The analyst believes that the myelopreservation data from this trial "may help bolster the available dataset" that the company is planning to bring to the FDA in the first half of 2019 for discussion regarding a viable path to approval. Messer adds that he looks forward to the "updated data from the randomized frontline SCLC trial of trilaciclib at ESMO in October".
09/17/18
HCWC
09/17/18
NO CHANGE
Target $79
HCWC
Buy
G1 Therapeutics price target raised to $79 from $61 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for G1 Therapeutics to $79 saying the company, in his opinion, makes positive revision to its Phase 2 protocol in newly diagnosed small cell lung cancer patients. The analyst views the earlier availability of comprehensive myelopreservation data as a positive that could add substantially to discussions with regulators in early 2019. Following the announcement of the revised protocol, White has increased confidence in the approval of trilaciclib. He keeps a Buy rating on G1 Therapeutics.
09/10/18
BTIG
09/10/18
INITIATION
Target $80
BTIG
Buy
G1 Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed G1 Therapeutics with a Buy rating and a price target of $80, citing the company's "unique" position of potentially developing two "best in class" CDK4/6 inhibitors - trilaciclib and lerociclib. The analyst notes that trilaciclib's positive outcomes support its efficacy and looks ahead to the 2nd line SCLC data later this year. Shrader adds that while the stock is no longer cheap, having risen nearly 400% since its IPO, "significant upside" in the stock price remains thanks to the "large market opportunity" of both programs that he estimates to be around $2B by 2025.
05/29/18
HCWC
05/29/18
INITIATION
Target $61
HCWC
Buy
G1 Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started G1 Therapeutics with a Buy rating and $61 price target. The company's trilaciclib could improve patient outcomes by maximizing the beneficial effects of chemotherapy, while minimizing myelosuppression and immunosuppression, White tells investors in a research note. He believes investors are missing the potential of trilaciclib, which he thinks become part of the standard of care for patients with CDK4/6-independent tumors, including small cell lung cancer and triple-negative breast cancer, that receive chemotherapy.

TODAY'S FREE FLY STORIES

ANGI

Angi Homeservices

$16.01

-0.52 (-3.15%)

14:45
03/25/19
03/25
14:45
03/25/19
14:45
Conference/Events
Angi Homeservices management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 27

    Mar

AAPL

Apple

$187.70

-3.41 (-1.78%)

14:43
03/25/19
03/25
14:43
03/25/19
14:43
Hot Stocks
Apple announces Apple TV+ service with exclusive original content »

Apple announced original…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

PCG

PG&E

$18.25

-0.9 (-4.70%)

14:40
03/25/19
03/25
14:40
03/25/19
14:40
Options
Big option prints in PG&E as shares drop 5.1% »

Big option prints in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$187.55

-3.56 (-1.86%)

14:38
03/25/19
03/25
14:38
03/25/19
14:38
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple TV+ pricing details…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$187.33

-3.78 (-1.98%)

14:38
03/25/19
03/25
14:38
03/25/19
14:38
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says TV+ will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

TIER

Tier REIT

$27.18

1.67 (6.55%)

, CUZ

Cousins Properties

$9.26

-0.62 (-6.28%)

14:33
03/25/19
03/25
14:33
03/25/19
14:33
Downgrade
Tier REIT, Cousins Properties rating change  »

Tier REIT downgraded to…

TIER

Tier REIT

$27.18

1.67 (6.55%)

CUZ

Cousins Properties

$9.26

-0.62 (-6.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 25

    Mar

  • 23

    Apr

UUUU

Energy Fuels

$3.19

0.04 (1.27%)

14:30
03/25/19
03/25
14:30
03/25/19
14:30
Options
Trader scoops up nearly 2K lotto ticket calls in Energy Fuels »

Trader scoops up nearly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$71.09

0.03 (0.04%)

14:28
03/25/19
03/25
14:28
03/25/19
14:28
Hot Stocks
Prologis CLO sells over 16,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

CRSP

Crispr Therapeutics

$33.86

-1.73 (-4.86%)

14:28
03/25/19
03/25
14:28
03/25/19
14:28
Conference/Events
Crispr Therapeutics management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

  • 08

    Apr

IONS

Ionis Pharmaceuticals

$78.76

-0.24 (-0.30%)

14:27
03/25/19
03/25
14:27
03/25/19
14:27
Conference/Events
Ionis Pharmaceuticals management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Apr

OESX

Orion Energy

$0.91

0.017 (1.90%)

14:25
03/25/19
03/25
14:25
03/25/19
14:25
Hot Stocks
Orion's Altschaefl says new products coming in April, May »

In an exclusive interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

AXSM

Axsome Therapeutics

$15.30

2.3 (17.69%)

14:25
03/25/19
03/25
14:25
03/25/19
14:25
Options
Axsome Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDAY

Workday

$189.95

-1.05 (-0.55%)

14:21
03/25/19
03/25
14:21
03/25/19
14:21
Hot Stocks
Workday says CIO McKenzie departing in April, Rhodes joining as new CIO »

In a blog post, Workday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
03/25/19
03/25
14:17
03/25/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
03/25/19
03/25
14:16
03/25/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$415.08

-1.92 (-0.46%)

, APO

Apollo Global

$27.93

-0.07 (-0.25%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Periodicals
BlackRock, Varde to make rival offers for Banca Carige, Reuters reports »

Varde Partners and…

BLK

BlackRock

$415.08

-1.92 (-0.46%)

APO

Apollo Global

$27.93

-0.07 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

F

Ford

$8.53

0.005 (0.06%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Options
Ford puts lead calls 6:1 »

Ford puts lead calls 6:1.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ASND

Ascendis Pharma

$115.50

-3.71 (-3.11%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Ascendis Pharma announces results of study of hypoparathyroidism at ENDO 2019 »

Ascendis Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.31

-2.8 (-1.47%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says Apple TV+ will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

IP

International Paper

$44.43

0.03 (0.07%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Options
International Paper call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.74

-2.37 (-1.24%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple CEO Tim Cook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

14:05
03/25/19
03/25
14:05
03/25/19
14:05
General news
Treasury Action: the $40 B 2-year note sale Tuesday »

Treasury Action: the $40…

AAPL

Apple

$188.48

-2.63 (-1.38%)

, ROKU

Roku

$67.67

4.15 (6.53%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03
Hot Stocks
Breaking Hot Stocks news story on Apple, Roku, Amazon.com »

Apple bringing Apple TV…

AAPL

Apple

$188.48

-2.63 (-1.38%)

ROKU

Roku

$67.67

4.15 (6.53%)

AMZN

Amazon.com

$1,762.35

-2.61 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    Jun

AAPL

Apple

$188.51

-2.6 (-1.36%)

, SNE

Sony

$42.00

-0.09 (-0.21%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03
Hot Stocks
Breaking Hot Stocks news story on Apple, Sony »

Apple bringing Apple TV…

AAPL

Apple

$188.51

-2.6 (-1.36%)

SNE

Sony

$42.00

-0.09 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

OESX

Orion Energy

$0.91

0.017 (1.90%)

, TM

Toyota

$120.19

0.39 (0.33%)

13:57
03/25/19
03/25
13:57
03/25/19
13:57
Hot Stocks
Orion CEO sees $11M Letter of Intent as 'very significant win' »

In an exclusive interview…

OESX

Orion Energy

$0.91

0.017 (1.90%)

TM

Toyota

$120.19

0.39 (0.33%)

F

Ford

$8.55

0.03 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.